甘露聚糖肽和地榆升白片治疗原发性胃恶性淋巴瘤化疗所致白细胞下降的临床效果  

Prospective randomized controlled clinical trial of mannan peptide and Diyu-Shengbai tablet to prevent white blood cell reduction of PGML patients with chemotherapy

作　　者：杨兰[1] 邓颖[1] 胡洪林[1] 潘海霞[1] 

机构地区：[1]四川省医学科学院四川省人民医院肿瘤科,成都610000

出　　处：《中国肿瘤临床与康复》2014年第7期792-795,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评价甘露聚糖肽和地榆升白片改善原发性胃恶性淋巴瘤(PGML)化疗中白细胞减少症的疗效及安全性。方法应用平行对照、前瞻性和开放性的方法,纳入137例PGML患者,随机分为甘露聚糖肽组(68例)和地榆升白片组(69例)。两组给药均为CHOP化疗方案的辅助药。检测两组外周白细胞水平、中性粒细胞水平和集落刺激因子用量,定期随访不良反应发生情况。结果甘露聚糖肽组和地榆升白片组显效率分别为51.7%和37.5%(P=0.03),第1周白细胞水平分别为(4.0±0.7)×109/L和(3.3±0.5)×109/L(P=0.04),第4周白细胞水平分别为(5.2±1.0)×109/L和(4.4±0.9)×109/L(P=0.035),第7周白细胞水平分别为(6.7±0.8)×109/L和(5.3±0.6)×109/L(P=0.006),人均里亚金用量分别为(0.79±1.28)支和(2.45±3.88)支(P=0.006)。两组患者未出现严重不良反应,甘露聚糖肽组出现不良反应的病例较少,且症状轻微,恢复较快。结论甘露聚糖肽和地榆升白片均能显著升高白细胞水平,甘露聚糖肽的临床疗效和安全性要优于地榆升白片。Objective To evaluate the efficacy and safety of mannan peptide and Diyu-Shengbai tablet on the white blood cell count of PGML patients with chemotherapy. Methods A prospective parallel randomized controlled clinical study was conducted to compare the efficacy and safety of 137 cases with pri- mary gastric malignant lymphoma, which were randomly divided into mannan peptide group（68patients） and Diyu-Shengbai tablet group （ 69 patients）. Both groups were given CHOP chemotherapy. White blood cell （ WBC）, neutrophil, as well as drug dose of rhG-CSF （ recombinant human granulocyte colony stimulating factor） were detected and the incidence of adverse reactions after two years follow-up were observed. Re- sults The data with a statistics difference between mannan peptide group and Diyu-Shengbai tablet group were the significant efficiency rate（51.7% vs 37. 5% ,P =0. 03） ,the number of WBC in first week（4. 0 ± O. 7 vs 3.3 ± 0. 5,P = O. 04 ）, in forth week （ 5.2 ± 1.0 vs 4. 4 ± 0. 9, P= 0. 035 ） and the seventh week （6. 7 ±O. 8 vs 5. 3 ± 0. 6, P = 0. 006）, and the means of used dose of rhG-CSF （ O. 79 ± 1.28 vs 2. 45 ± 3. 88, P = 0. 006）. There were few severe adverse reactions in the two groups after follow-up, and adverse re- actions in mannan peptide group were fewer. Conclusion Both of mannan peptide and Diyu-Shengbai tab- let and greatly rise white blood cell reduction of PGML Patients in chemotherapy. However, mannan peptide own better clinical effect and safety.

关 键 词：甘露聚糖肽 地榆升白片 白细胞减少症 原发性胃淋巴瘤 药物疗法 

分 类 号：R735.2[医药卫生—肿瘤]